Lombard Medical wins FDA approval for Aorfix; Agilent posts revenue quarterly income slump;

 @FierceMedDev: Cohera snags $17M to support TissuGlu. News | Follow @FierceMedDev

 @MarkHFierce: Weight loss devices never go out of style. BAROnova secured a $27.3M Series C for its contribution to the space. More | Follow @MarkHFierce

 @DamianFierce: St. Jude is studying whether renal denervation can treat heart attack and stroke in addition to hypertension. Press release | Follow @DamianFierce

> Despite a 3% revenue jump, Agilent ($A) pulled in just $179 million in net income last quarter, a 22% drop due in large part to costs associated with its $2.2 billion buyout of Dako. More

> SoniTrack Systems, a Stanford startup, is looking to use 3-D ultrasound and robotics to make radiation therapy for cancer more safe. Article

> SQI Diagnostics reported a $1.5 million loss in the fourth quarter, basically flat compared to the previous year, and the company says it is pursuing strategic alternatives, which could include going up for sale. News

> The FDA has issued an update on GE Healthcare's ($GE) Class I recall of infant resuscitation components, instructing physicians to carefully examine the units and remove those not already in use. Item

> Lombard Medical snagged FDA approval for the Aorfix stent, designed to treat abdominal aortic aneurysm. Story

> The FDA's William Maisel, chief scientist at CDRH, writes in his blog about how investigators felt as they approved Second Sight's Argus II, the first retinal implant the agency has OK'd. Post

Biotech News

 @FierceBiotech: Still trending: The 25 most influential people in biopharma today - 2013. Special Report | Follow @FierceBiotech

@JohnCFierce: Mega-mergers are back (expect 1-2 big deals in biopharma this year). News | Follow @JohnCFierce

@RyanMFierce: Japan takes lead in trialing a human stem cell therapy. Story | Follow @RyanMFierce

> GSK's Slaoui talks up 'innovative' late-stage pipeline as regulatory reviews loom. Article

> Biotech benefits from 'breakthrough' guess for its cancer med partnered with J&J. News

> Blog: AbbVie slams brakes on cancer drug trials after patient death. Report

Pharma News

@FiercePharma: Shire's Vyvanse tops $1B as more generics challenge Adderall. Report | Follow @FiercePharma

@EricPFierce: Mylan currently the focus of a hot rumor for picking up the sterile injectables unit of India's Strides Arcolab. News | Follow @EricPFierce

@AlisonBFierce: A promising new vaccine--administered as a nasal spray--is shrinking head and neck tumors. More | Follow @AlisonBFierce

> Seroquel XR patent upheld, protecting AZ blockbuster. News

> Premium pricing for Novo's Tresiba in EU, a tiny bit of good news. Story